Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
Schizophr Bull
; 49(2): 454-463, 2023 03 15.
Article
in En
| MEDLINE
| ID: mdl-36305696
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antipsychotic Agents
/
Cardiovascular Diseases
/
Metabolic Syndrome
/
Hypertension
Type of study:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Schizophr Bull
Year:
2023
Document type:
Article
Affiliation country:
United States
Country of publication:
United States